Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
AC ACAD ACADIA PHARMACEUTICALS INC FY ended Feb 18, 2026 | $29.11 | $5.02B | $5.09B | $1.07B | $150.66M | $391.00M | 12.66x | 4.68x | 33.81x |
VN VNDA Vanda Pharmaceuticals Inc. FY ended Feb 05, 2026 | $5.29 | $319.85M | $212.27M | $216.11M | -$130.54M | -$220.47M | -1.41x | 1.48x | — |
SA SAGE Sage Therapeutics, Inc. FY ended Feb 04, 2025 | — | — | — | $41.24M | -$399.64M | -$400.67M | — | — | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 36.47x | 2/4 | -$2.00B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.23x | 3/4 | $2.20B | $20.66 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -17.69x | 3/4 | $1.32B | $12.40 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
AC ACAD ACADIA PHARMACEUTICALS INC FY ended Feb 18, 2026 | $29.11 | $5.02B | $5.09B | $1.07B | $150.66M | $391.00M | 12.66x | 4.68x | 33.81x |
VN VNDA Vanda Pharmaceuticals Inc. FY ended Feb 05, 2026 | $5.29 | $319.85M | $212.27M | $216.11M | -$130.54M | -$220.47M | -1.41x | 1.48x | — |
SA SAGE Sage Therapeutics, Inc. FY ended Feb 04, 2025 | — | — | — | $41.24M | -$399.64M | -$400.67M | — | — | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 36.47x | 2/4 | -$2.00B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.23x | 3/4 | $2.20B | $20.66 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -17.69x | 3/4 | $1.32B | $12.40 | Peer averages are not economically meaningful for this method. |
